<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A low-dose Ara C (LDAC) regimen (0.2 mg/kg/d) was tried in two groups of eleven patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and in ten with hypoplastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) proven by biopsy </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, seven patients achieved complete remission (CR), but CR duration was rather short (4-9 months) </plain></SENT>
<SENT sid="2" pm="."><plain>Some cases showing relapse could be induced back into CR by the LDAC regimen </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients showed marked bone marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> before reaching CR </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, the main effect of LDAC was considered to be cytotoxic activity </plain></SENT>
<SENT sid="5" pm="."><plain>In one <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> patient, the karyotype of 47, XX, +8 at diagnosis was converted to <z:mpath ids='MPATH_458'>normal</z:mpath>, 46, XX after CR </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, there were no CR cases but five patients partially responded to the LDAC regimen </plain></SENT>
<SENT sid="7" pm="."><plain>One patient died of <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> soon after LDAC treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Three patients developed overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> and in one of them the disease was well controlled by LDAC over thirty months </plain></SENT>
<SENT sid="9" pm="."><plain>One patient with typical <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) suffered severe bone marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> after 12 mg/d for 10 days of LDAC, but one month later his hematopoiesis gradually recovered and reached a <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level (12 g/dl) </plain></SENT>
<SENT sid="10" pm="."><plain>However, <z:hpo ids='HP_0000001'>all</z:hpo> of his karotypes showed 45, XY, -7 at that time </plain></SENT>
<SENT sid="11" pm="."><plain>LDAC regimen is effective, especially for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, but may have a limited effect on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>